Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: A systematic review and meta-analysis

Irbaz Bin Riaz, Umar Zahid, Muhammad Umar Kamal, Muhammad Husnain, Ali McBride, Anh Hua, Auon Abbas Hamadani, Laeth George, Ali Zeeshan, Qurat Ul Ain Riaz Sipra, Ammad Raina, Bushra Rahman, Soham D Puvvada, Faiz - Anwer

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as well as safety of CD-19 and CD-20 chimeric antigen receptor-T therapy for B-cell hematologic malignancies. A total of 16 studies with 195 patients were identified. The pooled analysis showed an overall response rate of 61% (118/195) with complete response of 42% (81/195) and partial response of 19% (37/195). Major adverse events were cytokine release syndrome 33%, neurotoxicity 33% and B-cell aplasia 54%. Collectively, the results indicate encouraging response in relapsed/refractory B lymphoma and leukemia, especially in acute lymphoblastic leukemia (ALL) patients.

Original languageEnglish (US)
Pages (from-to)979-993
Number of pages15
JournalImmunotherapy
Volume9
Issue number12
DOIs
StatePublished - Sep 1 2017

Keywords

  • chimeric antigen T cells
  • hematological malignancy
  • leukemia
  • lymphoma
  • refractory
  • relapse

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: A systematic review and meta-analysis'. Together they form a unique fingerprint.

  • Cite this

    Riaz, I. B., Zahid, U., Kamal, M. U., Husnain, M., McBride, A., Hua, A., Hamadani, A. A., George, L., Zeeshan, A., Sipra, Q. U. A. R., Raina, A., Rahman, B., Puvvada, S. D., & Anwer, F. . (2017). Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: A systematic review and meta-analysis. Immunotherapy, 9(12), 979-993. https://doi.org/10.2217/imt-2017-0062